1. Ionotropic glutamate receptor antagonists and cancer therapy: time to think out of the box?

   • Mariana P. C. Ribeiro
   • José B. A. Custódio
   • Armanda E. Santos

   Review Article 01 September 2016 Pages: 219 - 225

   

2. The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer

   • Hongjing Zang
   • Weiyuan Wang
   • Songqing Fan

   Review Article 11 August 2016 Pages: 227 - 231

   

3. Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues

   • Bronwen J. Mayo
   • Andrea M. Stringer
   • Dorothy M. Keefe

   Review Article 21 October 2016 Pages: 233 - 249

   

4. Trends on polymer- and lipid-based nanostructures for parenteral drug delivery to tumors

   • Elham Ajorlou
   • Ahmad Yari Khosroushahi

   Review Article 15 October 2016 Pages: 251 - 265

   

5. Clinical research on rare diseases of children: neuroblastoma

   • Chiara Gerardi
   • Rita Banzi
   • Silvio Garattini

   Review Article 22 November 2016 Pages: 267 - 273

6. On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis

   • Jing Hu
   • Zhen Zhang
   • Xiaoping Qian

   Review Article 22 November 2016 Pages: 275 - 285

   

7. Research progress of hydroxychloroquine and autophagy inhibitors on cancer

   • Ting-Ting Shi
   • Xiao-Xu Yu
   • Hong-Tao Xiao

   Review Article 26 November 2016 Pages: 287 - 294

8. Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells

   • Jan S. Moreb
   • Deniz A. Ucar-Bilyeu
   • Abdullah Khan

   Review Article 10 December 2016 Pages: 295 - 301

9. Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1)

   • Muhammad Wasif Saif
   • Andrew Heaton
   • David M. Brown

   Review Article Open access 24 December 2016 Pages: 303 - 314

   

10. Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer

    • Jeffrey R. Infante
    • Amita Patnaik
    • Roger B. Cohen

    Original Article 17 January 2017 Pages: 315 - 326

    

11. Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205

    • Hong-Yan Zhang
    • Feng Liang
    • Xi-Gang Kang

    Original Article 06 January 2017 Pages: 327 - 337

    

12. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study

    • John Sarantopoulos
    • Alain C. Mita
    • Olivier Rixe

    Original Article Open access 05 January 2017 Pages: 339 - 351

    

13. Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer

    • Angelica L. Quartino
    • Hanbin Li
    • Amit Garg

    Original Article Open access 10 January 2017 Pages: 353 - 361

    

14. Myeloprotective effects of C-type natriuretic peptide on cisplatin-induced bone marrow granulocytopenia in mice

    • Masahiro Zenitani
    • Takashi Nojiri
    • Kenji Kangawa

    Original Article 18 January 2017 Pages: 363 - 368

    

15. The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy

    • Jianli Chen
    • Charalambos Solomides
    • Henry Simpkins

    Original Article 24 January 2017 Pages: 369 - 380

    

16. Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer

    • Samer Tabchi
    • Normand Blais
    • Mustapha Tehfe

    Original Article 12 January 2017 Pages: 381 - 387

    

17. Molecular explorations of substituted 2-(4-phenylquinolin-2-yl) phenols as phosphoinositide 3-kinase inhibitors and anticancer agents

    • Manikandan Alagumuthu
    • Sivakumar Arumugam

    Original Article 04 January 2017 Pages: 389 - 397

    

18. Modulation of cyclophosphamide-induced cardiotoxicity by methyl palmitate

    • Dina S. El-Agamy
    • Mohamed A. Elkablawy
    • Hany M. Abo-Haded

    Original Article 27 January 2017 Pages: 399 - 409

    

19. Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways

    • Hannes Liebig
    • Georg Günther
    • Gunnar Wichmann

    Original Article 21 January 2017 Pages: 411 - 420

    

20. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)

    • Ghassan K. Abou-Alfa
    • Chia-Jui Yen
    • Jorge A. Carrasquilo

    Original Article 24 January 2017 Pages: 421 - 429

    

21. Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report

    • Janet K. Coller
    • Joanne M. Bowen
    • Rachel J. Gibson

    Short Communication 23 December 2016 Pages: 431 - 434

    

22. Comment to: GSTP1, GSTM1 and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis

    • Sarah Cargnin
    • Salvatore Terrazzino

    Letter to the Editor 06 January 2017 Pages: 435 - 436

23. Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect?

    • Ian Joseph Cohen

    Letter to the Editor 09 January 2017 Pages: 437 - 437